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Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis
factor family that selectively induces apoptosis in cancer cells. However, gastric cancer cells are
insensitive to TRAIL. In the present study, we show that oxaliplatin enhanced TRAIL-induced apop-
tosis of MGC803, BGC823, and SGC7901 cells. Oxaliplatin promoted death receptor 4 (DR4) and death
receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent
nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.
Furthermore, the expression of the casitas B-lineage lymphoma (Cbl) family was downregulated by
oxaliplatin. Transfection of c-Cbl or Cbl-b partially reversed oxaliplatin-induced lipid raft aggrega-
tion. These results indicated that oxaliplatin enhanced TRAIL-induced gastric cancer cell apoptosis
at least partially through Cbl-regulated death receptor redistribution in lipid rafts.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Although chemotherapy improves the survival of advanced gas-
tric cancer patients, the median overall survival is no more than
12 months [1,2]. Accordingly, new therapeutic methods are worthy
of development. Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a member of the tumor necrosis factor (TNF) fam-
ily, and induces apoptosis in many cancer cells but spares most
normal cells. However, gastric cancer cells are insensitive to TRAIL
[3,4]. TRAIL binding to receptor 4 (DR4) and death receptor 5 (DR5)
results in receptor aggregation, and the death-inducing signaling
complex (DISC) formation, followed by sequential apoptosis [5,6].
Recent studies have shown that lipid rafts provide a membrane
platform for death receptors aggregation and play an important
role in initiating death signaling transmission [7,8]. This implieschemical Societies. Published by E
d apoptosis-inducing ligand;
factor; DR4, death receptor 4;
complex
.
s work.that the dysfunction of lipid raft maybe is one reason that gastric
cancer cells are insensitive to TRAIL.
Some chemotherapeutic drugs have been shown to sensitize
cancer cells to TRAIL [9–11]. Oxaliplatin is a third-generation
platinum-containing drug, and oxaliplatin-based regimens have
signiﬁcantly improved efﬁcacy compared with cisplatin-based
regimens in the treatment of colorectal cancer. Oxaliplatin is
also regarded as a promising drug for the treatment of gastric
cancer [12,13]. Cisplatin has the ability to sensitize colon cancer
cells to CD95 ligand by triggering lipid raft aggregation [14].
Whether oxaliplatin can enhance the sensitivity of gastric can-
cer cells to TRAIL by clustering death receptor into lipid rafts
is unknown.
The casitas B-lineage lymphoma (Cbl) family of ubiquitin
ligases is an important regulator of lipid rafts. It has been demon-
strated that c-Cbl and Cbl-b can sequester signaling molecules
from lipid rafts, which results in ineffective lipid raft aggregation
in T cells and mast cells [15–17]. Moreover, the loss of Cbl-b in T
cells triggers receptor clustering and lipid raft aggregation [18].
However, whether c-Cbl and Cbl-b can negatively regulate lipid
raft aggregation and therefore inﬂuence the sensitivity of gastric
cancer cells to TRAIL is not yet clear.lsevier B.V. All rights reserved.
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a combination of oxaliplatin and TRAIL. Our results for the ﬁrst
time showed that oxaliplatin enhanced TRAIL-induced gastric can-
cer cells apoptosis at least partially through Cbl-regulated death
receptor redistribution in lipid rafts.
2. Materials and methods
2.1. Reagents and antibodies
Recombinant human TRAIL was purchased from Cytolab/Pepro-
tech Asia (USA). Oxaliplatin was obtained from Sanoﬁ-Aventis. The
FITC-conjugated cholera toxin B subunit was from Sigma Chemical
Co. Rhodamine-conjugated goat anti-mouse IgG, anti-DR4, anti-
DR5, anti-procaspase-3, anti-procaspase-8, anti-Bax, anti-Bcl-2,
and anti-Cbl-b antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-c-Cbl antibody was purchased from
Transduction Laboratories (Lexington, KY).Fig. 1. Oxaliplatin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sy
regarded as a positive control. MGC803, BGC823, and SGC7901 cells were treated with ox
were treated with 5-FU (2 lg/mL) and TRAIL (100 ng/mL) for 48 h. (A) Cell viability was
ﬂow cytometry. (C) The mitochondrial membrane potential was analyzed by ﬂow cytom
analyzed by western blotting.2.2. Cell cultures and transfection
The gastric cancer cells were obtained from the Type Culture
Collection of the Chinese Academy of Sciences (Shanghai, China).
The cells were cultured in RPMI 1640 medium (Gibco) containing
10% heat-inactivated fetal bovine serum (FBS), penicillin (100
U/mL), and streptomycin (100 mg/mL) at 37 C under an atmo-
sphere of 95% air and 5% CO2. For transfection, cells were seeded
into six-well plates (5  105 cells/well) without antibiotics. After
24 h, cells were transfected with various plasmids using Lipofect-
amine 2000 reagent (Invitrogen, USA), according to the manufac-
turer’s instructions.
2.3. MTT assay
The cells were seeded at 5  104 cells/well in 96-well plates and
then exposed to oxaliplatin and/or TRAIL. Thereafter, 25 lL of MTT
solution (5 mg/mL) was added to each well and the cells werenergistically affected cell viability and cell apoptosis in gastric cancer cells. 5-FU was
aliplatin (at the respective IC50 doses) and TRAIL (100 ng/mL) for 24 h. MGC803 cells
determined by MTT assay. (B) The percentage of apoptotic cells was quantitated by
etry. (D) The expression of procaspase-3, procaspase-8, Bax and Bcl-2 proteins was
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200 lL of dimethylsulfoxide (DMSO) and the optical density (OD)
was measured at 570 nm with a microplate reader (Model 550,
Bio-Rad Laboratories, USA).
2.4. Flow cytometry analysis
The cells were seeded at 3  105 cells/well in six-well plates and
then exposed to oxaliplatin and/or TRAIL. The cells were collected
and incubated with 5 lL Annexin V and 10 lL PI for 15 min in the
dark. Moreover, mitochondrial depolarization was determined by
means of the cationic lipophilic ﬂuorochrome DiOC6. Cells were
collected and incubated with 20 nm DiOC6 for 15 min in the dark.
Finally, the samples were evaluated by ﬂow cytometry.
2.5. Western blot analysis
Cells were solubilized in 1% Triton lysis buffer on ice. Cell lysate
proteins were separated by polyacrylamide gel electrophoresis and
electrophoretically transferred to nitrocellulose membrane (Immo-
blin-P, Millipore, Bedford, MA, USA). The membranes were blocked
with 5% skim milk in TBST buffer, incubated with the indicated
antibodies and reacted with horseradish-peroxidase-conjugated
secondary antibodies. The immunoreactive proteins were visual-
ized with chemiluminescence reagent (SuperSignal Western Pico
Chemiluminescent Substrate, Pierce, USA).
2.6. Immunoﬂuorescence microscopy
The cells were seeded and treated in Lab-Tek chamber slides
(Nunc S/A, Polylabo, Strasbourg, France) and then ﬁxed in 3.3%
paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-
100 for 3 min and blocked with 5% bovine serum albumin (BSA).
For double staining, the cells were primed with anti-cholera toxin
B subunit, anti-DR4, or anti-DR5 antibody for 1 h and then incu-
bated with rhodamine-conjugated goat anti-mouse IgG forFig. 2. Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) cluster
with 22.56 lg/mL oxaliplatin, 100 ng/mL TRAIL, or a combination of both for 16 h. Then c
and analyzed by confocal ﬂuorescence microscopy. Original magniﬁcation, 40.45 min. The cells were mounted using the SlowFade Antifade Kit
(Molecular Probes, Eugene, OR), and analyzed by confocal ﬂuores-
cence microscopy (FV1000S-SIM/IX81, Olympus, Japan).
3. Results
3.1. Oxaliplatin enhanced TRAIL-induced apoptosis of MGC803,
BGC823, and SGC7901 cells
The synergistic activity of 5-FU + TRAIL on gastric cancer cells
has been demonstrated [19], so 5-FU was regarded as a positive
control. Our results showed that 100 ng/mL TRAIL resulted in a
slight reduction in cell viability and no more than 6% cell apoptosis
in three cell lines. Treatment with oxaliplatin (at the respective
IC50 doses) plus TRAIL (100 ng/mL) for 24 h resulted in a signiﬁcant
reduction in cell viability and increase in cell apoptosis compared
with treatment with oxaliplatin or TRAIL alone (Fig. 1A and B).
When two drugs were used in combination after 16 h, a higher de-
gree of mitochondrial depolarization, cleavage of procaspase-3 and
procaspase-8 and decreased expression of Bcl-2 were detected
(Fig. 1C and D). These results indicated that oxaliplatin enhanced
TRAIL-induced apoptosis through activation of mitochondria and
executive caspases in gastric cancer cells.
3.2. Oxaliplatin promoted DR4 and DR5 clustering into aggregated
lipid rafts
Recent study has shown that cisplatin induces CD95 clustering
into lipid rafts [14]. This led us to investigate whether oxaliplatin
can cluster death receptor into lipid rafts. Oxaliplatin (22.56
lg/mL) and TRAIL (100 ng/mL) were used in MGC803 cells for the
following experiments. As shown in Fig. 2, exposure to TRAIL alone
for 16 h did not induce obvious lipid raft aggregation or DR4 or DR5
clustering. However, oxaliplatin signiﬁcantly promoted the locali-
zation of DR4 andDR5 in aggregated lipid rafts. The combined treat-
ment with oxaliplatin and TRAIL showed similar results.ing into aggregated lipid rafts in MGC803 cells. Cells were left untreated or treated
ells were stained with anti-cholera toxin B subunit, anti-DR4 or anti-DR5 antibody,
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aggregation and DR4 and DR5 clustering, and decreased the apoptosis
To investigate the effects of lipid raft aggregation on cell apopto-
sis, nystatin, a cholesterol-sequestering agent that disrupted lipid
rafts, was used for next experiment. Interestingly, pretreatment
for 1 h with 50 lg/mL nystatin partially prevented lipid raft aggre-
gation and DR4 and DR5 clustering induced by oxaliplatin or
oxaliplatin + TRAIL (Fig. 3A) and signiﬁcantly suppressed oxalipla-Fig. 3. Nystatin partially prevented oxaliplatin-induced lipid raft aggregation and death r
MGC803 cells. Cells were either exposed to 50 lg/mL nystatin for 1 h or not, then left untr
both. (A) Cells were stained with anti-cholera toxin B subunit, anti-DR4 or anti-DR
magniﬁcation, 40. (B) The percentage of apoptotic cells was quantitated by ﬂow cytomtin + TRAIL-induced apoptosis (Fig. 3B). These results suggested
that oxaliplatin-induced DR4 and DR5 clustering in aggregated lipid
rafts facilitated TRAIL-induced gastric cancer cell apoptosis.
3.4. Oxaliplatin downregulated the expression of c-Cbl and Cbl-b
Recent studies have shown that ubiquitin ligases c-Cbl and Cbl-
b are negative regulators of lipid rafts [15,16]. Our data showed
that oxaliplatin alone strongly reduced c-Cbl and Cbl-b proteineceptor 4 (DR4) and death receptor 5 (DR5) clustering, and reduced the apoptosis in
eated or treated with 22.56 lg/mL oxaliplatin, 100 ng/mL TRAIL, or a combination of
5 antibody, and analyzed by confocal ﬂuorescence microscopy at 16 h. Original
etry at 24 h.
Fig. 4. Oxaliplatin downregulated the expression of c-Cbl and Cbl-b in MGC803 cells. (A) Cells were left untreated or treated with 22.56 lg/mL oxaliplatin for 1 h, 8 h, 16 h, or
24 h. (B) Cells were left untreated or treated with 22.56 lg/mL oxaliplatin, 100 ng/mL TRAIL, or a combination of both for 16 h. The expression of c-Cbl and Cbl-b was analyzed
by western blotting.
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induced the downregulation of c-Cbl and Cbl-b, similar to exposure
to oxaliplatin alone at 16 h (Fig. 4B). These results suggested that
oxaliplatin-induced DR4 and DR5 clustering into lipid rafts might
be triggered by downregulation of c-Cbl and Cbl-b.
3.5. Overexpression of c-Cbl and Cbl-b partially reversed oxaliplatin-
induced lipid raft aggregation
To conﬁrm that c-Cbl and Cbl-b negatively regulate lipid raft
aggregation, we transiently transfected c-Cbl and Cbl-b into
MGC803 cells. As shown in Fig. 5A, lipid raft aggregation was par-
tially reversed by c-Cbl, Cbl-b, and c-Cbl and Cbl-b compared with
the control. The expression of c-Cbl and Cbl-b was shown in Fig. 5B.
These results indicated that c-Cbl and Cbl-b partially reversed
oxaliplatin-induced lipid raft aggregation.
4. Discussion
TRAIL selectively induces cancer cell apoptosis. Oxaliplatin has
been shown to sensitize colon cancer cells to TRAIL [20,21]. In
the present study, when MGC803, BGC823, and SGC7901 cells
were treated with 100 ng/mL TRAIL for 24 h, the proportion of
apoptotic cells was no more than 6%, indicating that three cell linesFig. 5. The overexpression of c-Cbl and Cbl-b partially reversed oxaliplatin-induced lipid
Cbl, Cbl-b, or a combination of both for 48 h. (A) Cells were then left untreated or treated
then stained with anti-cholera toxin B subunit, anti-DR4 or anti-DR5 antibody, and analy
of transfection, the expression of c-Cbl and Cbl-b was analyzed by western blotting.were insensitive to TRAIL. But oxaliplatin signiﬁcantly enhanced
TRAIL-induced gastric cancer cells apoptosis through intrinsic
and extrinsic apoptosis pathways.
Lipid rafts provide a membrane platform for death receptor
aggregation and trigger death signaling transmission. In our study,
TRAIL failed to induce obvious lipid raft aggregation or DR4 or DR5
clustering. This was probably one reason that gastric cancer cells
were insensitive to TRAIL. Some agents, such as cisplatin, edelfo-
sine and quercetin, can cause death receptor clustering into lipid
rafts [22,23]. Our results showed that oxaliplatin promoted DR4
and DR5 clustering into aggregated lipid rafts and enhanced
TRAIL-induced apoptosis in gastric cancer cells. The cholesterol-
sequestering agent nystatin partially prevented lipid raft aggrega-
tion and DR4 and DR5 clustering, and reduced the apoptosis. These
data suggested that the integrity of lipid rafts was necessary for
death receptor clustering.
Ubiquitin ligases c-Cbl and Cbl-b are negative regulators of lipid
rafts. Our previous studies showed that translocation of Cbl-b into
the lipid raft regulated the functions of some signaling molecules
and resulted in inefﬁcient lipid raft aggregation [16,17]. Krawczyk
et al. conﬁrmed that the loss of Cbl-b resulted in the enhancement
of lipid raft aggregation [18]. In the present study, oxaliplatin sig-
niﬁcantly downregulated the expression of c-Cbl and Cbl-b. Mean-
while lipid raft aggregation occurred. Overexpression of c-Cbl andraft aggregation in MGC803 cells. Cells were transfected with plasmids encoding c-
with 22.56 lg/mL oxaliplatin, 100 ng/mL TRAIL, or a combination of both for 16 h,
zed by confocal ﬂuorescence microscopy. Original magniﬁcation, 40. (B) After 48 h
948 L. Xu et al. / FEBS Letters 583 (2009) 943–948Cbl-b partially suppressed lipid raft aggregation. These results sug-
gested that the translocation of Cbl proteins played a role in regu-
lating lipid raft aggregation.
In summary, our results demonstrated that oxaliplatin
enhanced TRAIL-induced apoptosis in gastric cancer cells. The
synergistic antitumor mechanism was associated with oxalipla-
tin-induced lipid raft aggregation and DR4 and DR5 clustering.
DR4 and DR5 redistributed in lipid rafts in response to oxaliplatin-
induced downregulation of the Cbl family.
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